PTD-DBM 5mg

1. 1

   Clean the rubber stoppers of both the PTD-DBM vial and the bacteriostatic water container using fresh, sterile alcohol swabs and allow them to air dry thoroughly.

2. 2

   Draw exactly 2.0 mL of bacteriostatic water into a calibrated syringe.

3. 3

   Insert the syringe needle into the peptide vial at an angle, directing the fluid slowly down the glass interior wall to minimize shear forces on the powder.

4. 4

   Allow the mixture to stand undisturbed for 30 seconds to initiate passive dissolution.

5. 5

   Gently swirl or roll the vial between the palms until the lyophilized cake is fully dissolved, strictly avoiding vigorous shaking.

6. 6

   Store the completed stock solution inside a dedicated laboratory refrigerator held steadily between 2°C and 8°C.

Overview

PTD-DBM (Protein Transduction Domain-Dishevelled Binding Motif) is a synthetic laboratory-engineered peptide built to target the negative feedback loop governing Wnt/β-catenin pathway activity. By incorporating an octa-arginine cell-penetrating peptide tethered to a distinct regulatory peptide sequence, it serves as a competitive antagonist against the CXXC5 protein. Because CXXC5 naturally binds Dishevelled to shut down ongoing regenerative signals, the decoy peptide prevents this interaction and permits sustained activation of downstream cellular cascades. Preclinical interest centers largely on the modulation of anagen hair cycle induction, epidermal wound healing, and follicle neogenesis. Disruption of CXXC5 function has been correlated with reduced fibrotic scarring and rescued hair follicle growth in rodent models exposed to miniaturization triggers such as prostaglandin D2 and dihydrotestosterone. Despite wide discussion within non-clinical and cosmetic science communities, in vivo research remains preclinical, originating predominantly from animal model experiments without human trial validation. Laboratory handling requires careful consideration of its topical formulation and biochemical vulnerabilities. Containing two sensitive cysteine residues, the molecule is susceptible to oxidative degradation in aqueous diluents. Most protocols rely on immediate serial dilution or incorporation into topical hydrogels and carriers rather than classical parenteral methods, demanding strict low-temperature maintenance and clean preparation standards.

1. 1.Lee SH, et al., J Exp Med, 2015 — Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing; introduces PTD-DBM at 100 µM topical dosing.
2. 2.Lee SH, et al., J Invest Dermatol, 2017 — CXXC5 targeting by competitor peptide accelerates hair regrowth and wound-induced hair follicle neogenesis in mice.
3. 3.Ryu YC, et al., Cells, 2023 — CXXC5 downstream mediation of DHT and PGD2 in alopecia models, with rescue via PTD-DBM.
4. 4.Lee SH, et al., Adv Healthc Mater, 2023 — Hyaluronic-acid hydrogel patch delivery of PTD-DBM combined with valproic acid for regenerative wound healing.
5. 5.Kim HY, et al., EMBO Mol Med, 2016 — Small molecule inhibitors targeting the Dishevelled-CXXC5 interface for bone anabolism.
6. 6.Seo SH, et al., Clin Transl Med, 2022 — CXXC5 interaction inhibition via small molecules reversing metabolic dysfunction.
7. 7.Mehta A, et al., Cells, 2025 — Review on hair follicle neogenesis and Wnt/β-catenin pathway modulators.
8. 8.Ma S, et al., J Comput Aided Mol Des, 2018 — Structural characterization and computational modeling of the Dvl-CXXC5 binding domain.

Peptide VialView

Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.